Compare · BASI vs INCY
BASI vs INCY
Side-by-side comparison of Bioanalytical Systems, Inc. (BASI) and Incyte Corp. (INCY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BASI and INCY operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- INCY carries a market cap of $26.29B.
- INCY has hit the wire 8 times in the past 4 weeks while BASI has been quiet.
- INCY has more recent analyst coverage (25 ratings vs 0 for BASI).
- Company
- Bioanalytical Systems, Inc.
- Incyte Corp.
- Price
- -
- -
- Market cap
- -
- $26.29B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1997
- News (4w)
- 0
- 8
- Recent ratings
- 0
- 25
Incyte Corp.
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor for the treatment of adults; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug that is in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase III clinical trial to treat naïve chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; and Cellenkos, Inc., as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Latest BASI
- SEC Form RW filed by Bioanalytical Systems, Inc.
- SEC Form 8-K filed by Bioanalytical Systems, Inc.
- Bioanalytical Systems, Inc. Announces Corporate Name Change to Inotiv, Inc.
- Bioanalytical Systems, Inc., doing business as Inotiv, Announces Plan to Expand Service Offerings to Include Cardiovascular Safety Pharmacology
- Bioanalytical Systems, Inc., doing business as Inotiv, Invests in Additional Vivarium Capacity at Facility in West Lafayette, IN
- SEC Form 8-K filed
- Colliers Securities resumed coverage on Bioanalytical Systems with a new price target
- SEC Form 4: Beth Taylor bought $88,500 worth of Common Shares (5,000 units at $17.70), increasing direct ownership by 17% to 34,295 units
- Bioanalytical Systems, Inc., doing business as Inotiv, to Participate in the H.C. Wainwright Global Life Sciences Virtual Conference
- SEC Form EFFECT filed
Latest INCY
- President, Global Head of R&D Cagnoni Pablo J sold $1,356,174 worth of shares (10,801 units at $125.56), decreasing direct ownership by 6% to 183,200 units (SEC Form 4)
- Canaccord Genuity initiated coverage on Incyte with a new price target
- Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- President, Global Head of R&D Cagnoni Pablo J sold $1,305,422 worth of shares (10,640 units at $122.69), decreasing direct ownership by 5% to 204,804 units (SEC Form 4)
- EVP & Chief Scientific Officer Mayes Patrick A exercised 2,207 shares at a strike of $106.47 and sold $273,646 worth of shares (2,207 units at $123.99) (SEC Form 4)
- President, Global Head of R&D Cagnoni Pablo J sold $1,901,794 worth of shares (15,888 units at $119.70), decreasing direct ownership by 7% to 215,444 units (SEC Form 4)
- EVP & Chief Scientific Officer Mayes Patrick A exercised 45,767 shares at a strike of $78.48 and sold $5,734,376 worth of shares (47,954 units at $119.58), decreasing direct ownership by 3% to 61,441 units (SEC Form 4)
- New Chemotherapy-Free Immunotherapy Combination for Follicular Lymphoma Listed on the PBS
- Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis
- SEC Form 10-Q filed by Incyte Corp.